Research Analysts’ Weekly Ratings Changes for Teva Pharmaceutical Industries (TEVA)

A number of firms have modified their ratings and price targets on shares of Teva Pharmaceutical Industries (NYSE: TEVA) recently:

• 9/23/2026 – Teva Pharmaceutical Industries is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $50.00 price target on the stock.
• 9/9/2026 – Teva Pharmaceutical Industries is now covered by Leerink Partners. They set an “outperform” rating and a $45.00 price target on the stock.
• 9/8/2026 – Teva Pharmaceutical Industries was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 9/4/2026 – Teva Pharmaceutical Industries had its price target raised by UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 8/21/2026 – Teva Pharmaceutical Industries was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/12/2026 – Teva Pharmaceutical Industries had its price target raised by Barclays PLC from $40.00 to $42.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Teva Pharmaceutical Industries was upgraded by Weiss Ratings from “sell (d-)” to “hold (c-)”.
• 7/28/2026 – Teva Pharmaceutical Industries had its price target raised by Piper Sandler from $42.00 to $44.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. This represents a 46.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 374,959 shares of company stock worth $14,644,285. 0.54% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.